Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 34,593 shares, an increase of 411.8% from the August 15th total of 6,759 shares. Based on an average daily trading volume, of 31,550 shares, the short-interest ratio is currently 1.1 days. Currently, 2.4% of the company’s stock are short sold.

Global X Genomics & Biotechnology ETF Stock Up 0.8%

GNOM stock traded up $0.50 during midday trading on Friday, hitting $62.47. The company’s stock had a trading volume of 5,895 shares, compared to its average volume of 17,958. Global X Genomics & Biotechnology ETF has a 52-week low of $36.13 and a 52-week high of $68.00. The firm has a market capitalization of $91.20 million, a P/E ratio of -26.70 and a beta of 1.19. The firm has a 50-day simple moving average of $59.41 and a 200-day simple moving average of $51.42.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently announced a semiannual dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were paid a dividend of $0.0579 per share. This represents a yield of 20.0%. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is presently -27.35%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after buying an additional 10,308 shares in the last quarter. Sei Investments Co. lifted its stake in Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Global X Genomics & Biotechnology ETF by 30.9% during the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares in the last quarter. Creative Financial Designs Inc. ADV grew its holdings in Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after acquiring an additional 481 shares in the last quarter. Finally, Wealth Management Partners LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the 1st quarter valued at approximately $244,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.